Anti‐infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response
Dreesen, E., Van Stappen, T., Ballet, V., Peeters, M., Compernolle, G., Tops, S., Van Steen, K., Van Assche, G., Ferrante, M., Vermeire, S., Gils, A.
Published in Alimentary pharmacology & therapeutics (01.02.2018)
Published in Alimentary pharmacology & therapeutics (01.02.2018)
Get full text
Journal Article
Web Resource
Review article: pharmacological aspects of anti‐TNF biosimilars in inflammatory bowel diseases
Papamichael, K., Van Stappen, T., Jairath, V., Gecse, K., Khanna, R., D'Haens, G., Vermeire, S., Gils, A., Feagan, B. G., Levesque, B. G., Vande Casteele, N.
Published in Alimentary pharmacology & therapeutics (01.11.2015)
Published in Alimentary pharmacology & therapeutics (01.11.2015)
Get full text
Journal Article
247P A population-based survey on the knowledge, perception and attitudes towards rare diseases and gene therapy in Belgium: focus on Duchenne muscular dystrophy
Van Stappen, T., Verschelden, M., Samyn, W., Minnebo, J., Mommen, M.
Published in Neuromuscular disorders : NMD (01.10.2024)
Published in Neuromuscular disorders : NMD (01.10.2024)
Get full text
Journal Article
336P Quantifying the burden-of-illness of Duchenne muscular dystrophy in Belgium: an interim analysis of a site-based survey
De Waele, L., Cremers, J., Debien, E., Gielis, E., Maenen, V., Vanoppen, I., Van Stappen, T., Beeckman, L., Posner, N., Dukacz, S., Jiang, L., Evans, J., Wu, Y., Jones, C., Meeus, L., Claeys, K.
Published in Neuromuscular disorders : NMD (01.10.2024)
Published in Neuromuscular disorders : NMD (01.10.2024)
Get full text
Journal Article
P694 Validation of two commercial assays for therapeutic drug monitoring of adalimumab biosimilars
Berghmans, R, Naudts, J, Ferkinghoff, B, Gören, H, Henke, M L, Lennerz, A, Van Stappen, T
Published in Journal of Crohn's and colitis (15.01.2020)
Published in Journal of Crohn's and colitis (15.01.2020)
Get full text
Journal Article
DOP029 Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post-hoc analysis of the taxit trial
Van Stappen, T., Vande Casteele, N., Van Assche, G., Ferrante, M., Vermeire, S., Gils, A.
Published in Journal of Crohn's and colitis (01.02.2017)
Published in Journal of Crohn's and colitis (01.02.2017)
Get full text
Journal Article
P637 Anti-infliximab antibody concentrations guide therapeutic decision-making in patients with Crohn's disease losing clinical response
Dreesen, E., Van Stappen, T., Ballet, V., Tops, S., Compernolle, G., Van Assche, G., Ferrante, M., Vermeire, S., Gils, A.
Published in Journal of Crohn's and colitis (01.02.2017)
Published in Journal of Crohn's and colitis (01.02.2017)
Get full text
Journal Article
P527 Low adalimumab serum levels at Week 4 provoke immunogenicity and influence therapy outcome in anti-TNF naïve Crohn’s disease patients
Verstockt, B, Moors, G, Bian, S, Van Stappen, T, Tops, S, Ballet, V, Van Assche, G, Vermeire, S, Gils, A, Ferrante, M
Published in Journal of Crohn's and colitis (16.01.2018)
Published in Journal of Crohn's and colitis (16.01.2018)
Get full text
Journal Article